Wegovy doses in ml: what the volume figures on your pen actually mean

What the trial data and licensed specifications actually confirm about Wegovy's ml figures

The STEP 1 trial, published in the New England Journal of Medicine, established semaglutide 2.4 mg once weekly as the maintenance dose for weight management, producing an average body-weight reduction of around 15% over 68 weeks. What the headlines rarely explain is the delivery mechanism: the active ingredient is carried in a fixed 0.75 ml injection volume regardless of the strength of the pen. This is confirmed in Wegovy's Summary of Product Characteristics, accessible through the Electronic Medicines Compendium (eMC), which specifies each pre-filled pen as a 0.75 ml solution for subcutaneous injection.

The practical consequence is straightforward. When your dose increases from 0.5 mg to 1.0 mg, the injection feels identical, same pen, same plunger travel, same 0.75 ml deposited under the skin. What changes is the concentration of semaglutide in that fluid. Novo Nordisk achieves this by formulating each strength separately, not by asking patients to draw up different volumes. There is nothing to measure, no syringe graduation to read. You cannot accidentally give yourself more or less by misjudging a volume.

This design choice matters for anyone who has previously used insulin or other injectables measured in units or millilitres. With Wegovy, the pen handles all of that. For a detailed breakdown of how each pen organises its doses across the cartridge, our guide to the four-dose structure of each Wegovy pen explains what sits behind the mechanism.

Why the ml figure stays fixed while semaglutide strength climbs

Pharmaceutical manufacturers balance two competing demands when formulating an injectable: they want a volume large enough to dissolve the drug reliably, and small enough to be comfortable under the skin. Subcutaneous injections above roughly 1–2 ml can cause local discomfort and unpredictable absorption. Novo Nordisk landed on 0.75 ml as the standard for Wegovy's entire range.

That means concentration does the heavy lifting. The 0.25 mg starting pen contains approximately 0.33 mg of semaglutide per ml; the 2.4 mg maintenance pen contains approximately 3.2 mg per ml, roughly ten times more active ingredient packed into the same carrier volume. For a full picture of how each Wegovy dose is structured across the titration schedule, the concentrations rise steadily while the 0.75 ml volume remains constant throughout. The pen auto-doses, locks after use and incorporates a covered needle, there is no volume adjustment for the patient to consider at any stage.

If you have ever held two Wegovy pens of different strengths and wondered why they look the same size, this is why. The physical differences between Wegovy pen strengths come down to labelling and colour-coding, not physical dimensions. A quick check before each injection: compare the coloured label on your pen against the strength your prescriber confirmed at your last review. That takes under a minute and catches the most common confusion.

The 7.2 mg pen and what MHRA approval changed about the volume picture

The MHRA approved the single-dose 7.2 mg semaglutide pen on 14 April 2026, making it the highest-strength Wegovy format currently authorised in the UK. Trials at this dose reported around 20.7% average weight loss over 72 weeks, figures that narrow the gap with tirzepatide at its highest licensed strength. The government announcement confirming the 7.2 mg pen's approval clarifies it is licensed for adults with a BMI of 30 or above, not for the cardiovascular indication, and that the starting dose remains 0.25 mg with prescriber-guided titration. If you are wondering whether Wegovy has a fifth dose beyond the standard four-step titration, the 7.2 mg pen is precisely where that question leads.

Critically, the volume principle holds: it is still a subcutaneous injection in the same general format. The mechanism is updated (auto-dosing with a built-in covered needle that locks after use) but patients are not asked to measure or calculate millilitres at any point. The ml figure remains a background specification rather than an active patient task.

If you are curious about how many individual doses sit within a single pen across the titration schedule, this page explains the dose count per pen in plain terms. And for a broader grounding in how semaglutide works as a treatment, the Wegovy treatment overview covers mechanism, eligibility and what to expect.

What this means practically if you are considering Wegovy

Most people arrive at the ml question through entirely reasonable curiosity: they want to understand what they are injecting before they start. That instinct is good. The honest answer is that Wegovy's fixed-volume design simplifies the injection experience considerably, you do not manage the volume, and neither does your pharmacist. What your prescriber does manage, carefully, is which concentration is right for you at each four-week interval.

Wegovy is available in the UK through private prescription and, for those who meet strict eligibility criteria, through NHS specialist weight management services. The NHS route involves waiting lists that are currently long in most areas. Private treatment through a regulated online pharmacy is an alternative for people who do not meet NHS criteria yet, or who prefer not to wait. Our weight-loss treatment page sets out what a consultation with our prescribers looks like, including the clinical assessment that determines which treatment, and which starting point, suits you.

Wegovy is not recommended during pregnancy, breastfeeding, or for anyone trying to conceive. It is not licensed for under-18s. A clinical review before every prescription, including repeat orders, is how responsible prescribing works, there is no shortcut that keeps you safe.

If you are ready to speak to a prescriber about whether semaglutide is appropriate for you, start your free consultation with the nume clinical team.